Gastric cancer+: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Waddell, T ^a   Verheij, M ^b   Allum, W ^c   Cunningham, D ^a   Cervantes, A ^d   Arnold, D ^e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

^e TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RAMUCIRUMAB; TRASTUZUMAB;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER STAGING; ENDOSCOPIC SURGERY; FOLLOW UP; GASTRECTOMY; HER 2 POSITIVE GASTRIC CANCER; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; TREATMENT PLANNING;

ADENOCARCINOMA; CARCINOMA; COMBINED MODALITY THERAPY; HUMANS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885345842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt344     Document Type: Article

References (48)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
2. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-649.
3. Fitzgerald RC, Hardwick R, Huntsman D et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444.
4. Nath J, Moorthy K, Taniere P et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008; 95: 721-726.
5. de Graaf GW, Ayantunde AA, Parsons SL et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33: 988-992.
6. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours, 7th edition. Oxford: Wiley-Blackwell 2009.
7. Edge S, Byrd D, Compton C et al. AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer 2010.
8. Tada M, Tanaka Y, Matsuo N et al. Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol 2000; 15(Suppl): D98-102.
9. Gotoda T, Iwasaki M, Kusano C et al. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868-871.
10. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
11. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
12. Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
13. Jiang L, Yang KH, Guan QL et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. J Surg Oncol 2013; 107: 807-814.
14. Dikken JL, van Sandick JW, Allum WH et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013; 100: 83-94.
15. Memon MA, Khan S, Yunus RM et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-1789.
16. Haverkamp L, Weijs TJ, van der Sluis PC et al. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. Surg Endosc 2013; 27: 1509-1520.
17. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
18. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
19. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
20. Smalley SR, Benedetti JK, Haller DG et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333.
21. Dikken JL, Jansen EP, Cats A et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010; 28: 2430-2436.
22. Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
23. Lee J, Lim do H, Kim S et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273.
24. Zhu WG, Xua DF, Pu J et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012; 104: 361-366.
25. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
26. Sasako M, Sakuramoto S, Katai H et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393.
27. Noh SH, Park SR, Yang HK et al. Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: Final results from the CLASSIC trial. Ann Oncol 2013; 24(suppl. 4): iv14.
28. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
29. Starling N, Rao S, Cunningham D et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
30. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534.
31. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457.
32. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
33. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
34. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
35. Ford H, Marshall A, Wadsley J et al. COUGAR-02: A randomised phase III study of docetaxel versus active symptom control in advanced oesophagogastric adenocarcinoma. J Clin Oncol (Meeting Abstracts) Feb 2013; 31.
36. Roy AC, Park SR, Cunningham D et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013; 24: 1567-1573.
37. Ueda S, Hironaka S, Yasui H et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol (Meeting Abstracts) May 2012; 30.
38. Tey J, Back MF, Shakespeare TP et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007; 67: 385-388;
39. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-684.
40. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697.
41. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976.
42. Fuchs CS, Tomasek J, Cho JY et al. REGARD: a phase III, randomized, doubleblinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. J Clin Oncol (Meeting Abstracts) 2013; 31.
43. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND):a randomised, open-label phase 3 trial Lancet Oncol 2013; 14: 490-499.
44. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489.
45. Ferry DR, Dutton SJ, Mansoor W et al. Phase III multi-centre, randomised, doubleblind, placebo-controlled trials of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (cancer oesophagus gefitinib). Ann Oncol 2012; 23(suppl. 9): ixe12 (LBA20_PR).
46. Allum WH, Blazeby JM, Griffin SM et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472.
47. IGCC Working Group. The Charter Scaligero on Gastric Cancer: Follow-Up After Gastrectomy for Cancer. 10th International Gastric Cancer Congress (IGCC); 2013.
48. D'Ugo D, Biondi A, Tufo A, Persiani R. Follow-up: The evidence. Dig Surg 2013; 30: 159-168.